RXRX Stock Analysis: Buy, Sell, or Hold?
RXRX - Recursion Pharmaceuticals, Inc. Class A Common Stock
$2.84
-0.10 (-3.40%)
▼
5d:
-12.07%
30d:
-22.62%
90d:
-33.18%
WAIT
LOW Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 04, 2026
Smart Money Accumulation
RXRX is down 9.5% this week, but smart money is accumulating calls. Top strike: $4 2026-06-18 with 6,071 OI. Call ratio: 61% View Scanner →
Strength: 5.8/10
Get Alerted When RXRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: RXRX is down 12.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: RXRX is down 12.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: RXRX is currently trading at $2.84, which is considered oversold relative to its 30-day fair value range of $3.19 to $3.63.
Technical Outlook: Technically, RXRX is in a strong downtrend. The price is currently testing key support at $2.80. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.4% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.71 (+136.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, RXRX is in a strong downtrend. The price is currently testing key support at $2.80. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.4% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.71 (+136.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$3.19 -
$3.63
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
Protect Your Profits
Holding RXRX? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.4%)
- BULLISH: Trading 136.4% below Wall St target ($6.71)
- WARNING: Recommendation downgraded due to -12.1% 5-day decline - wait for stabilization
Fair Price Analysis
30-Day Fair Range
$3.19 -
$3.63
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$2.80
Resistance Level
$3.50
Current Trend
Strong Downtrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.34
Wall Street Target
$6.71
(+136.4%)
Revenue Growth (YoY)
681.7%
Share & Embed Analysis
Last updated: March 31, 2026 8:31 AM ET
Data refreshes hourly during market hours. Next update: 9:31 AM
Data refreshes hourly during market hours. Next update: 9:31 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RXRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
8
Sells
Net
INSIDERS SELLING
Recent Transactions
Ben R Taylor
SELL
7956 shares
2026-03-17
Najat Khan
SELL
28298 shares
2026-03-09
Ben R Taylor
SELL
13426 shares
2026-02-18
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$25 | 52 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$213 | 67 BUY |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$33 | 49 HOLD |
|
IMVT
Immunovant Inc |
STRONG BUY
14 analysts |
$40 | 57 HOLD |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$43 | 56 HOLD |
Advanced RXRX Option Strategies
Professional options setups generated by AI based on today's RXRX price and gamma walls.
